Shinpoong Pharmaceutical supplies treatments to malaria eradication support projects in the United States.
Shinpoong Pharmaceutical announced on the 14th that it has decided to supply malaria treatment ‘Pyramax’ to the US government’s ‘Global Malaria Eradication Support Initiative (PMI)’. The explanation is that it was selected as a supplier by participating in a public procurement bid in 2025.
PMI is an initiative under the U.S. President led by the U.S. Agency for International Development (USAID), in collaboration with the U.S. Centers for Disease Control and Prevention (CDC), and overseen by the U.S. Global Malaria Coordinator in consultation with interagency advisory groups. Since its launch in 2005 to eradicate malaria, it has been supporting global public procurement in cooperation with several international organizations.
Malaria causes approximately 250 million patients and nearly 620,000 deaths in Africa and Asia. In particular, as the number of patients increases due to problems such as resistance to existing treatments and difficulties in treatment arise, the need for new treatments has emerged. Accordingly, the International Organization for the Purchasing of Pharmaceutical Products (UNITAID) has recently actively recommended Pyramax as an alternative treatment, solidifying its position in the malaria treatment market.
In fact, Pyramax is listed as a primary treatment in 11 African countries (Nigeria, Guinea, Democratic Republic of the Congo, Republic of the Congo, Côte d’Ivoire, Niger, Cameroon, etc.), and is also exported to 11 African Union countries.
Yoo Je-man, CEO of Shinpoong Pharmaceutical, said, “Pyramax’s exports this year will reach 10 billion won, and exports are expected to increase significantly through success in large-scale global public procurement bidding in the future.” “It is very meaningful that it is a process of being recognized as a standard treatment,” he said.
Source: kormedi.com
